This is a translation of the Swedish press release published 2023-08-15, 08.00 CEST

Neola Medical AB (publ) today publishes the Q2 report of 2023 (in Swedish). The report is available at the company’s website and is attached to the press release.

During the quarter, the company has worked intensively in the product development with technical verification studies, regulatory work and meeting with the FDA. The company has participated at the largest conference for neonatology in the U.S. and visited neonatal intensive care units in Europe to enlarge the company’s network of key opinion leaders and create an early interest in Neola®. The market preparation work with focus on the U.S. market has been intensified through the opening of an office in Palo Alto, Silicon Valley, at Nordic Innovation House, at the same time as the company has gotten a stronger IP-protection through a new patent in the U.S.

Read the entire press release (in Swedish) here: Press release (in Swedish)